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Abstract
The antiphospholipid syndrome was initially
described in 1986. To reassess the validity of
antiphospholipid antibodies in systemic lupus
erythematosus (SLE), 95 patients with SLE
were studied. Their antiphospholipid antibody
profile was analysed and correlated with
clinical findings such as thrombosis, abor-
tions, or thrombocytopenia. A low prevalence
of these antibodies was found (13 patients;
14%) with a high specificity for thrombosis
(92%) and abortions (92%).
The importance ofanticardiolipin antibodies
as a risk factor for thrombosis or abortions, or
both, in patients with SLE is reaffirmed by
this work.
Work carried out over the past few years has led
to the definition of the antiphospholipid syn-
drome as the association of thrombosis, re-
current abortion, and thrombocytopenia with
anticardiolipin antibodies and/or the detection
of lupus anticoagulant activity in the patient's
plasma.'
Initial work on this subject showed a high
incidence (36-60%) of anticardiolipin antibodies
in patients with systemic lupus erythematosus
(SLE) and confirmed the association of the
clinical and laboratory findings defined in the
antiphospholipid syndrome.7'9
To assess the validity of the definition more
than five years after the initial description of
this syndrome, we decided to study our own
population of patients with SLE and to deter-
mine the prevalence of anticardiolipin antibodies
and their correlation with thrombosis, abortions,
and thrombocytopenia.
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Patients and methods
Ninety five consecutive patients with SLE
attending the lupus outpatients clinic at St
Thomas's Hospital, London during a six month
period were included in this study.
All patients fulfilled four or more of the
American Rheumatism Association classification
criteria for SLE.'° At the time of their consulta-
tion, serum samples were collected for labora-
tory analysis and relevant past clinical and
laboratory data were obtained.
Ninety two of the patients were women and
three were men, with a mean age of 38-6 (range
17-66) years. The anticardiolipin antibodies
were determined in this laboratory by an enzyme
linked immunoabsorbent assay (ELISA) as
described previously." The results were ex-
pressed as GPL units (immunoglobulin G (IgG))
and MPL units (IgM) and classified as negative,
low, moderate, or high positive according to the
recommendations of the 1987 workshop on
standardisation of the test for anticardiolipin
antibodies. 2
The results were compared with those of
serum samples obtained from 95 normal blood
donors matched for sex and age.
The conventional Fisher's exact test was used
to determine the statistical significance of the
clinical and laboratory findings. The sensitivity
and specificity of the anticardiolipin antibodies
for thrombosis and abortions were determined
according to the method of Galen and
Gambino. 13
Results
Of the 95 patients, 13 (14%), were positive for
anticardiolipin antibodies, all 13 being positive
for IgG and two also for IgM. No positive
results were found among the control subjects
(p<0005). Eight of the 13 patients with positive
anticardiolipin antibody results (62%) fulfilled
the criteria of the antiphospholipid syndrome,
six patients having had thrombosis and abortions
and two having had either thrombosis or abor-
tions. Six patients had moderate or high levels
of IgG anticardiolipin antibodies (figure).
Eighteen patients (19%) had a past history of
venous or arterial thrombosis. The presence of
these events was significantly higher among
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patients with anticardiolipin antibodies (7/13;
53%) than among those without (11/82; 13%)
(p<0 005). When we tested the sensitivity of
anticardiolipin antibodies for thrombosis, we
found that of the 18 patients with thrombosis,
seven had anticardiolipin antibodies (sensitivity
39%). In addition, when we tested the specificity,
we found that of the remaining 77 patients
without thrombosis, 71 had no anticardiolipin
antibodies (specificity 92%).
Twenty one patients (22%) had had recurrent
abortions. The incidence of these events was
also significantly higher among patients with
anticardiolipin antibodies (7/13; 54%) than
among those without (14/80; 18%) (p<0-01).
When we tested the sensitivity of anticardiolipin
antibodies for recurrent abortions, we found
that of the 21 patients who had had abortions,
seven had anticardiolipin antibodies (sensitivity
33%). In addition, when we tested the specifi-
city, we found that of the remaining 72 patients
without recurrent abortions, 68 had no anti-
cardiolipin antibodies (specificity 92%).
Twelve patients (13%) had thrombocytopenia,
but no association with the presence of anti-
cardiolipin antibodies was found.
Discussion
In this series of patients, levels of IgG anti-
cardiolipin antibodies were strongly associated
with thrombosis and abortions. This reinforces
previous findings stressing such an association.4
Although the time between the events and the
determinations of the anticardiolipin antibody
titres was variable in our study, the finding of
this association is of great importance. As noted
by Harris, patients with IgG anticardiolipin
antibodies who have had thrombosis or abortions
are at a higher risk for developing such clinical
events in the future. 14 15 On the other hand, the
IgM isotype seems to be less specific for the
antiphospholipid syndrome.
The overall prevalence of anticardiolipin anti-
bodies was only 14%. The reported prevalence
of anticardiolipin antibodies in patients with
SLE has varied widely.'6 This variability is
almost certainly due to the cut off positive level
and to patient selection. In this ELISA only
values exceeding five GPL or 3-2 MPL units
were considered positive. This corresponds to
five standard deviations (SD) above that of the
normal population. In a large number of
published reports, results of two SD above
normal are considered positive. In early studies
carried out in our laboratory a prevalence of
61% was found using a cut off for positivity of
2-97 SD.2 Thus the rigidity of our standardised
ELISA for anticardiolipin antibodies might
explain in part the low incidence of anticardio-
lipin antibodies in this group of patients.
Another factor that might have influenced our
results is that all patients were receiving some
treatment by the time their blood was collected
for analysis.'7
As a result of the association of thrombocyto-
penia with increased levels of anticardiolipin
antibodies in some patients with SLE,'8 it has
been suggested that these antibodies may
immunologically alter the platelets, rendering
them suitable targets for destruction. '" However,
Haga et al, using a flow cytometry technique,
have failed to show a significant specific binding
ofaffinity purified IgG anticardiolipin antibodies
to resting or thrombin activated platelets.20 In
this study, confirming the results obtained by
others,21 22 no significant correlation was found
between the levels of anticardiolipin antibodies
and platelet counts.
Although the mechanism of action of anti-
phospholipid antibodies is still unclear, the
presence ofthese antibodies should be considered
a risk factor for thrombosis and abortions in
patients with SLE.
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